Home News Insights Trading halts Paper trading Guide Community My account

Market calendarNext market opening

Display in USD

Loading news article.

U.S. stock guide
Scanner guide
Paper trading guide
Terms of service
Privacy policy
Announcements
FAQ

Support: help@wapeb.comPartnerships: partnership@wapeb.com

WAPE is a free research, analysis and paper trading service. It does not place real securities orders. Market data and AI summaries are for information only, not investment advice or stock recommendations. Information may include delays, errors or estimates. Check original sources and supporting materials. You are responsible for your investment decisions and any resulting gains or losses.

Language한국어 English

Loading news article.

vTv Therapeutics Announces First Participant Randomized in Phase 2a Pilot Study Evaluating Cadisegliatin in Individuals with Type 1 Diabetes (T1D) Using Hybrid Closed-Loop (HCL) Insulin Delivery Systems | WAPE

Back All news

NewsGlobeNewswire

vTv Therapeutics Announces First Participant Randomized in Phase 2a Pilot Study Evaluating Cadisegliatin in Individuals with Type 1 Diabetes (T1D) Using Hybrid Closed-Loop (HCL) Insulin Delivery Systems

Oct 27, 2026, 08:00 ET · Published

View source

Article summary

Phase 2a pilot study aims to inform the design and conduct of future Phase 3 research in this population

An excerpt from the original article.

Related companies

vTv Therapeutics Inc. Class A Common StockVTVTView stock

vTv Therapeutics Announces First Participant Randomized in Phase 2a Pilot Study Evaluating Cadisegliatin in Individuals with Type 1 Diabetes (T1D) Using Hybrid Closed-Loop (HCL) Insulin Delivery Systems

Article summary

Related companies

Analyzed by WAPE AI.

Comments —